阿西替尼; 阿昔替尼； 319460-85-0;Axitinib 新品

产品描述

等级：活性药物成分（API）

化学名称:N-Methyl-2 - ({3 - [(E) - 2 - (2-pyridinyl)乙烯基]1 h-indazol-6-yl} sulfanyl)苯甲酰胺分子式:C22H18N4OS

分子量:386.470

规范：按照ChP/USP/EP建立企业标准外观:粉

总杂质：不大于0.5%

纯度：不低于99%

残留溶剂：完全符合ICH Q3C要求 致突变杂质：完全符合ICH M8

亚硝胺评估：可用

粒度：可根据客户要求进行普通级或研磨/筛分

储存方法：室温

生产能力：商用

标准包装：1kg/袋，5kg/袋，或根据客户要求

产品用途

Axitinib由辉瑞公司以Inlyta®品牌销售，于2012年1月获得FDA批准，用于治疗晚期肾细胞癌（RCC），特别是在其他全身治疗失败后。阿西替尼通过抑制血管内皮生长因子(VEGF)/VEGF受体酪氨酸（RTK）信号通路减缓癌细胞增殖。特别是，axitinib是一种有效的VEGF/RTK 1-3抑制剂，可选择性地减缓实体肿瘤中的血管生成、血管通透性和血流。 

联系方式

四川青木制药有限公司

四川省眉山市东坡区经济开发区东区顺江大道南段55号

国际营销部(International):

Email: sales@eastonpharma.cn 

Tel: 028-87827187

国内营销部(Mainland)：

李经理 13880480517   

杨经理 15982276454

Product Description

• Grade: Active Pharmaceutical Ingredient(API)

• Chemical Name:N-Methyl-2-({3-[(E)-2-(2-pyridinyl)vinyl]-1H-indazol-6-yl}sulfanyl)benzamide

• Molecular Formula:C22H18N4OS

• Molecular Weight:386.470

• Specification: Enterprise Standard established according   to ChP/USP/EP

• Appearance: Powder

• Total impurities: not more than 0.5%

• Purity: not less than 99%

• Residual Solvents: fully comply with ICH Q3C

• Mutagenic impurities: fully comply with ICH M8

• Nitrosamine assessment: available

• Particle size: regular grade or milling/sieving according to      customer’s requirement.

• Storage: Room temperature

• Production capacity: Commercial

• Standard Package: 1kg/bag, 5kg/bag, or      according to the customer’s requirement

Applications

• Sold under the brand name Inlyta® by Pfizer, Inc., Axitinib was approved by the FDA in January 2012 for the treatment of advanced renal cell carcinoma (RCC), specifically after the failure of other systemic treatments. Axitinib slows cancer cell proliferation by inhibition of the vascular endothelial growth factor (VEGF)/VEGF receptor tyrosine (RTK) signaling pathway.

  In particular, axitinib is a potent inhibitor of VEGF/RTK 1-3, which selectively slows angiogenesis, vascular permeability, and blood flow in solid tumors.

Contact Information

Sichuan Qingmu Pharmaceutical Co., Ltd.

Add: No. 55, South Shunjiang Avenue, East Economic Development Zone, Dongpo District, Meishan City, Sichuan, 620036, China

International Marketing Department: 

Email: sales@eastonpharma.cn 

Tel: 0086-28-87827187